|
Post by peppy on May 19, 2016 23:52:58 GMT -5
Another Tweet today: Mike Castagna Mike Castagna – @castagna2011 A Team is in place! Thank you to everyone who accepted offers this week. One last opening let's see who the lucky person will be! #winning! Someone on YMB said that Mike had tweeted that there were 5000 applicants for 50 jobs. I went to find that tweet but it wasn't there. It would not surprise me if they did have that kind of response. The sales team is hired and I am sure the advertising theme is done or near done. Exciting times. I am apprehensive, the plan seems to be the same plan sanofi had, get the physicians on board.
|
|
|
Post by buyitonsale on May 20, 2016 0:14:09 GMT -5
I am trying to find any info here about the actual business plan... You know, what kind of prescription numbers are targeted by this sales team on a monthly or quarterly basis.
There is a plan, right?
|
|
|
Post by roseylv on May 20, 2016 1:38:41 GMT -5
I am trying to find any info here about the actual business plan... You know, what kind of prescription numbers are targeted by this sales team on a monthly or quarterly basis. There is a plan, right? g Mike gave a response to a question during the last conference call. Read the transcript in the Q&A I think. And YES, there is a plan! Where have you been? MNKD 2.0!!!
|
|
|
Post by liane on May 20, 2016 4:38:37 GMT -5
Yes, there is a plan. There were comments / questions from the audience re DTC to drive demand. Mike emphasized that this would not be cost-effective at this point. He also emphasized that physicians have to be educated - how to prescribe, spiro requirement, titration, simplifying the prior auth, etc - all before patients spike the demand. This is where he is picking up the ball that SNY dropped. Toward this initial goal:
* The cadre of diabetic nurse educators * Making available a low cost spirometer and educating physicians that they don't need a full pulmonary function test * A hotline for prior auth's - so that the physicians's office will receive a simple form tailored to the pt's specific insurance * New titration sample boxes and instruction in how to accomplish it
|
|
|
Post by esstan2001 on May 20, 2016 8:20:28 GMT -5
Another Tweet today: Mike Castagna Mike Castagna – @castagna2011 A Team is in place! Thank you to everyone who accepted offers this week. One last opening let's see who the lucky person will be! #winning! Someone on YMB said that Mike had tweeted that there were 5000 applicants for 50 jobs. I went to find that tweet but it wasn't there. It would not surprise me if they did have that kind of response. The sales team is hired and I am sure the advertising theme is done or near done. Exciting times. I am apprehensive, the plan seems to be the same plan sanofi had, get the physicians on board.
Peppy, The difference is that Sanofi did not do anything. And if they did, in terms of focus on target, they had maybe 200 reps dedicated to covering 50,000 PCP's; Mike is targeting 50-70 reps to 5000-7000 Endo's by my recollection. MNKD is staffed 1 to 100; Sanofi was staffed 1 to 250. Mike is also actively working the PBM's, spirometry, and drop out issues (titration, copays, etc). Sanofi apparently was not. Did you not make it to the meeting?
|
|
|
Post by babaoriley on May 20, 2016 9:24:08 GMT -5
Those SNY reps weren't selling just Afrezza (heck, they would have starved!). Huge difference. SNY would have been fine if they gave it 100%, but with the change of CEO's, Afrezza was shuffled down - too bad for many diabetics that may have been helped significantly and too bad for us, as we go back to square one. But this time, MNKD will be in control and the reps work for MNKD.
|
|
|
Post by BlueCat on May 20, 2016 10:01:32 GMT -5
Yes, there is a plan. There were comments / questions from the audience re DTC to drive demand. Mike emphasized that this would not be cost-effective at this point. He also emphasized that physicians have to be educated - how to prescribe, spiro requirement, titration, simplifying the prior auth, etc - all before patients spike the demand. This is where he is picking up the ball that SNY dropped. Toward this initial goal: * The cadre of diabetic nurse educators * Making available a low cost spirometer and educating physicians that they don't need a full pulmonary function test * A hotline for prior auth's - so that the physicians's office will receive a simple form tailored to the pt's specific insurance * New titration sample boxes and instruction in how to accomplish it To be fair - any GTM plan worth its salt should include: 1. Purpose 2. Goals/objective (e.g. sales/market projections WRT to market opportunity)3. Tactics to achieve (with timeline/roadmap) 4. Resources (aka: $) 5. KPIs/success metrics - with ROI based on #4 against #26. Caveats/dependencies 7. Thank You .... Seems to me we've got 1, 3, and some of 6 and 7. The pieces the investors and analyts really need to hear are 2, 4 and 5. And we're not hearing it. Which is alarming as anyone going out and beginning execution should have this clearly in sight. Have I missed it recently - were any of those elements covered at the ASM? The most I've caught is a little on 4 - that though they acknowledge Symphony/IMS data are incomplete, they represent trending. Mike seems really seasoned, so have a hard time believing he's not got it already in his plan. For sure, he's been given a budget (that's what he's hiring off of) Comments? * to clarify - I think there is a complete MNKD 2.0 plan, I just don't think we've completely heard it - per above. ** Lots of clean up edits. Sorry - caffeine not activated yet ... need to titrate better
|
|
|
Post by agedhippie on May 20, 2016 10:03:49 GMT -5
Those SNY reps weren't selling just Afrezza (heck, they would have starved!). Huge difference. SNY would have been fine if they gave it 100%, but with the change of CEO's, Afrezza was shuffled down - too bad for many diabetics that may have been helped significantly and too bad for us, as we go back to square one. But this time, MNKD will be in control and the reps work for MNKD. It's the ham and eggs scenario - the chicken is involved, but the pig is committed! Contrary to what is often said I believe prior to the CEO change Sanofi were serious about this, but if it didn't work they could live with that. Mannkind on the otherhand absolutely have to make this work.
|
|
|
Post by kball on May 20, 2016 10:21:57 GMT -5
Those SNY reps weren't selling just Afrezza (heck, they would have starved!). Huge difference. SNY would have been fine if they gave it 100%, but with the change of CEO's, Afrezza was shuffled down - too bad for many diabetics that may have been helped significantly and too bad for us, as we go back to square one. But this time, MNKD will be in control and the reps work for MNKD.I was thinking this exact phrase last night. I suppose Mannkind could have chosen it as their catch phrase. Glad they went with Mannkind 2.0 instead
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 20, 2016 11:44:07 GMT -5
|
|
|
Post by cm5 on May 21, 2016 7:23:39 GMT -5
Dear Mr. Agedhippie and your expressed concerns re "cancer"---
Cancer and inhalants---Insulin is not a carcinogen---rather, prolonged presence of insulin reduces liver production of IGF binding proteins---
Diabetes as a Risk Factor of Pancreatic Cancer Li, Donghui. Mao, Yixiang. (2015). Diabetes as a Risk Factor of Pancreatic Cancer.
Pancreapedia: Exocrine Pancreas Knowledge Base, DOI: 10.3998/panc.2015.2
Unbound (bioavailable) IGF1 enhances somatic growth
Dis Model Mech. 2011 Sep; 4(5): 649–658.
Published online 2011 May 31. doi: 10.1242/dmm.006775 Sebastien Elis,1,* Yingjie Wu,1,* Hayden-William Courtland,1 Dara Cannata,1 Hui Sun,1 Mordechay Beth-On,1 Chengyu Liu,2 Hector Jasper,3 Horacio Domené,3 Liliana Karabatas,3 Clara Guida,3 Jelena Basta-Pljakic,4 Luis Cardoso,4 Clifford J. Rosen,5 Jan Frystyk,6 and Shoshana Yakar1
|
|
|
Post by cm5 on May 21, 2016 8:33:09 GMT -5
More re: "concerns about cancer" and insulin---
Report below is complex, detailed, meticulous discussion of the problems with IGF and human insulin analogues---and the real concerns about IGF and cancer:
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Sci Rep. 2016; 6: 23320.
Published online 2016 Mar 17. doi: 10.1038/srep23320
PMCID: PMC4794765
Elrashdy M. Redwan,a,1,2 Moustafa H. Linjawi,3 and Vladimir N. Uverskyb,1,4,5 1Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia 2Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg EL-Arab 21934, Alexandria, Egypt 3Department of Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia 4Department of Molecular Medicine and USF Health Byrd Alzheimer’s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA 5Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation, Russia aEmail: moc.oohay@1691nawder bEmail: ude.fsu.htlaeh@yksrevuv
|
|
|
Post by cm5 on May 21, 2016 11:20:16 GMT -5
More details about "cancer concerns"---
We should be concerned about the glargines----
Increased Intrinsic Disorder Propensity in Some Insulin Analogues as a Marker of their Increased Mitogenicity
In other words, this report discusses the evaluation of insulin analogues in terms of confirmational stability, ie how flexible, unraveled, or exposed----
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Sci Rep. 2016; 6: 23320. Published online 2016 Mar 17. doi: 10.1038/srep23320 Elrashdy M. Redwan,a,1,2 Moustafa H. Linjawi,3 and Vladimir N. Uverskyb,1,4,5 1Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia 2Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, New Borg EL-Arab 21934, Alexandria, Egypt 3Department of Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia 4Department of Molecular Medicine and USF Health Byrd Alzheimer’s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA 5Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation, Russia aEmail: moc.oohay@1691nawder bEmail: ude.fsu.htlaeh@yksrevuv
|
|
|
Post by cm5 on May 21, 2016 12:02:40 GMT -5
Re: Confirmational stability-----"whereas the flexibility of this central region increases in the following order: Detemir/Degludec < AspB10 = insulin = Aspart = Lispro < Glulisin < Glargin = AspB10/Glargine"------
Could this be a reason for the #2 position (as of March 31, 2016) of Renaissance Technologies LLC, Novo-Nordisk AS ADR ?
|
|
|
Post by LosingMyBullishness on May 21, 2016 12:09:35 GMT -5
Re: Confirmational stability-----"w hereas the flexibility of this central region increases in the following order: Detemir/Degludec < AspB10 = insulin = Aspart = Lispro < Glulisin < Glargin = AspB10/Glargine"------ Could this be a reason for the #2 position (as of March 31, 2016) of Renaissance Technologies LLC, Novo-Nordisk AS ADR ? I assume that you really digged into this, so my question is: why and how was inhaled insulin connected to lung cancer? What was the argument that stick so much that it became a dogma?
|
|